Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 13 14 15 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Inositec–Halsin Partners: public relations, 201610 service existent by Halsin Partners 2016-10-27
Inositec–SEVERAL: investment, 201610 seed financing round CHF1.4m ($1.42m) from VI Partners via Venture Incubator Fund + Zürcher Kantonalbank 2016-10-27
Cyprotex–Evotec: investment, 201610–201612 acquisition £55.7m=€66.3m in cash for all 26.1m shares + funding of all debt 2016-10-26
Nordic Nanovector–Wilex: antibody-drug conjugates, 201610– collab developm of ADCs for leukemias with Heidelberg Pharma 2016-10-26
NBE Therapeutics–PPF Group: investment, 201610–201611 PPF commits to invest CHF10m in next financing round of NBE as part of collab w Sotio as 2016-10-20
PPF Group–NBE Therapeutics: antibody-drug conjugates, 201610– collab + license agreem of NBE + Sotio as 2016-10-20
Schwabe Pharmaceuticals–ACD/Labs: cheminformatics, 201610– supply deployment of ACD/Spectrus platform by Willmar Schwabe Pharmaceuticals 2016-10-19
ADC Therapeutics–SEVERAL: investment, 201610 private financing round $105m incl Auven Therapeutics + Wild Family Office + AstraZeneca 2016-10-18
Science 37–Novartis: investment, 201610 financing round Series B totalling $31m incl existing + co-investor dRx Capital 2016-10-18
Science 37–SEVERAL: investment, 201610 financing round Series B $31m led by Redmile Group + incl Lux Capital + dRx Capital + SGBV 2016-10-18
Hookipa–Austria (govt): grant, 201610 5th FFG grant €4.16m to develop arenavirus vector-based cancer immunotherapies 2016-10-17
ObsEva–SEVERAL: investment, 201610–201701 IPO $96.75m+$14.513m w 645k+967.5k common shares at $15/share at Nasdaq Global Select Market 2016-10-17
Max Planck–Labfolder: electronic lab notebook, 201610– supply license for up to 11k MPI researchers using Labfolder s/w 2016-10-12
UgiSense–SEVERAL: investment, 201610 first financing round €1.2m from private investors 2016-10-12
Merck (DE)–HTG: molecular companion diagnostics, 201610– collab master CDx agreement with HTG Molecular Diagnostics 2016-10-11
Helsinn–Consilium: public relations, 201610 service existent by CSC 2016-10-10
Mei Pharma–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA 2016-10-10
OncoResponse–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA 2016-10-10
QuantuMDx–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA 2016-10-10
Selexis–Sam Brown: public relations, 201610 service existent by Sam Brown Inc 2016-10-10
Newron–SEVERAL: investment, 201610 capital increase CHF26.1m private placement 1.32m new shares at CHF19.75/share 2016-10-06
Kibion–Mayoly Spindler: investment, 201610 acquisition of Kibion AB by Mayoly Spindler 2016-10-05
Probiodrug–SEVERAL: investment, 201610 capital increase €14.9m w 744k new shares at €20/share representing 10% of issued share capital 2016-10-05
Carrick Therapeutics–Evotec: drug discovery services, 201610– collab strategic alliance discovery + preclinical services for novel oncology targets 2016-10-04
Carrick Therapeutics–Evotec: investment, 201610 1st financing round totalling $95m incl up to $6m from co-investor Evotec AG 2016-10-03
Carrick Therapeutics–SEVERAL: investment, 201610 1st financing round $95m co-led by ARCH Venture Partners + Woodford Investment 2016-10-03
Bellevue–SEVERAL: investment, 201610–201612 initial offering £150m + listing at LSE of BB Healthcare Trust plc managed by Bellevue Asset Management AG 2016-10-01
Depomed–Grünenthal: pain drug, 201609 collab existent cebranopadol developm + marketing rights for US for Depomed 2016-09-30
EngMab–Celgene: investment, 201609 acquisition of EngMab AG for $600m 2016-09-30
Noxxon–OTHER: investment, 201609 listing of ordinary shares on Alternext Paris [no new shares issued] 2016-09-30
Noxxon–SEVERAL: investment, 201609 private placement just prior to listing of ordinary shares on Alternext Paris 2016-09-30
Bluebird Bio–Medigene: TCR technology, 201609– collab strategic alliance $15m upfront + up to over $1b funding/milestones + royalties 2016-09-29
Boehringer–Hospital Corp of America: clinical research, 201609– collab clinical developm of combi of 2 checkpoint inhibitors w Sarah Cannon Research 2016-09-29
ICMP–Qiagen: MDx forensics, 201609– collab developm NGS workflow for identification of missing persons 2016-09-29
Boehringer–ViraTherapeutics: cancer immunotherapy, 201609– long-term collab up to €210m to develop oncolytic virus platform + products 2016-09-28
Immunic–4SC: immune modulatory compounds, 201609 acquisition of small molecule immunology portfolio of 4SC by Immunic 2016-09-28
Noxxon–NewCap: public relations, 201609 service existent by NewCap 2016-09-28
Immunic–Bavaria (govt): investment, 201609 financing round Series A totalling €17.5m incl co-investor Bayern Kapital 2016-09-27
Immunic–High-Tech Gründerfonds: investment, 201609 financing round Series A totalling €17.5m incl co-investor HTGF 2016-09-27
Immunic–Life Sciences Partners: investment, 201609 financing round Series A totalling €17.5m co-led by LSP V + LifeCare Partners 2016-09-27
Immunic–LifeCare Partners: investment, 201609 financing round Series A totalling €17.5m co-led by LSP V + LifeCare Partners 2016-09-27
Immunic–SEVERAL: investment, 201609 financing round Series A €17.5m co-led by LSP + LifeCare Partners 2016-09-27
NeuRoWeg project–Grünenthal: companion diagnostics, 201609– Grünenthal is partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
NeuRoWeg project–Life & Brain: companion diagnostics, 201609– Life & Brain GmbH is partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
NeuRoWeg project–North Rhine-Westphalia (govt): grant, 201609– EFRD/NRW €1.5m grant to develop test for efficacy of neuropathic pain drugs 2016-09-27
NeuRoWeg project–Univ Bonn: companion diagnostics, 201609– Univ Hospital Bonn is partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
NeuRoWeg project–Univ Cologne: companion diagnostics, 201609– Univ Hospital Cologne partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
Mologen–Global Derivative Trading: credit, 201609– convertible bond with total nominal value of €2.54m by largest investor GDT 2016-09-26
MVZ HZMD Trier–Bruker Corp: mass spectrometer, 201610 supply existent of MALDI Tissuetyper solution 2016-09-25
Evotec–France (govt): cancer drug discovery, 201609– research collab with Inserm in translational oncology 2016-09-22
iOmx Therapeutics–Akampion: public relations, 201609 service existent by Akampion 2016-09-22
iOmx Therapeutics–SEVERAL: investment, 201609 financing round Series A €40m co-led by MPM Capital + Sofinnova Partners 2016-09-22
Lipotype–Germany (govt): grant, 201609 support for Skin Lipidomics developm from Central Innovation Programme for SMEs 2016-09-22
Scienion–Berlin (govt): investment, 201609 DIVESTMENT IBB Beteiligungsgesellschaft sells its shareholding in Scienion AG 2016-09-22
Artios Pharma–SEVERAL: investment, 201609 financing round Series A £25m led by SV Life Sciences 2016-09-21
Bayer–Evotec: drug discovery services, 201609– collab 5y €14m minimum + €300m milestones + royalties multi-target research for kidney diseases 2016-09-21
Roche–BioNTech: mRNA technology, 201609– collab ww $310m upfront + near-term milestones + cost-profit-sharing developm mRNA cancer therapies Genentech 2016-09-21
Organobalance–Novo Group: investment, 201609 acquisition €na of Organobalance GmbH by Novozymes 2016-09-15
AC Immune–SEVERAL: investment, 201609 US IPO $66m net $57.8m net with 6m common shares at $11/share at Nasdaq 2016-09-13
Mologen–SEVERAL: investment, 201609–201610 capital increase €13.6m 11.316m common shares at €1.2/share (raising no. of existing shares by up to 50%) 2016-09-13
PaxVax–Leukocare: drug formulation technology, 201609– license to SPS technology for one live viral vaccine product of PaxVax 2016-09-13
TATAA Biocenter–Basepair: bioinformatics, 201609– collab TATAA to offer Basepair’s data analysis s/w for NGS 2016-09-13
Inflazome–Fountain Healthcare Partners: investment, 201609 financing round Series A totalling $17m incl founding investor FHP 2016-09-12
Inflazome–Novartis: investment, 201609 financing round Series A totalling $17m incl founding investor Novartis Venture Fund 2016-09-12
Inflazome–SEVERAL: investment, 201609 financing round Series A $17m from Novartis Venture Fund + Fountain Healthcare Partners 2016-09-12
Lonza–Harvard Univ: AAV vectors, 201609– license to use Anc-AAV technology from Massachusetts Eye and Ear 2016-09-12
CRISPR Therapeutics–SEVERAL: investment, 201609–201610 US IPO $56m+$8.4m with 4m+600k shares at $14/share at Nasdaq Global Market 2016-09-09
Bayer–Helmholtz: plant science, 201609– collab strategic research 5y phenotyping for products by Bayer CropScience + FZJ 2016-09-08
Vivasure Medical–SEVERAL: investment, 201609 financing round Series C €16.2m led by LSP Health Economics Fund + co-led by Evonik VC 2016-09-08
Curetis–Siemens: GEAR database, 201609 acquisition €na of ww rights to GEAR database + related IP + know-how by Curetis from STA 2016-09-07
Oncovision–Bruker Corp: investment, 201609 acquisition €na of preclinical imaging business of Oncovision by Bruker 2016-09-07
Pure Communications–W2O Group: investment, 201609 acquisition €na of Pure Communications by W2O Group 2016-09-07
Biomeva–Asahi Glass: investment, 201609 acquisition 100% of Biomeva GmbH by Asahi Glass 2016-09-06
Rigontec–Boehringer: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor BIVF 2016-09-06
Rigontec–Forbion: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Forbion Capital Partners 2016-09-06
Rigontec–High-Tech Gründerfonds: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor HTGF 2016-09-06
Rigontec–MacDougall Biomedical Communications: public relations, 201609 service existent by MacDougall 2016-09-06
Rigontec–Mitsubishi Chemical: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor MP Healthcare 2016-09-06
Rigontec–North Rhine-Westphalia (govt): investment, 201609 financing round Series A 3rd + final closing totalling €15m w returning investor NRW.BANK 2016-09-06
Rigontec–SEVERAL: investment, 201609 financing round Series A 3rd + final closing €15m from existing investors 2016-09-06
Rigontec–Sunstone Capital: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Sunstone Capital 2016-09-06
Rigontec–Wellington Partners: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Wellington 2016-09-06
IBI-Lorenzini–Celonic: cell line development, 201609– collab using CHOvolution to establish cell lines for RnD 2016-09-05
Unigeo Agricultura de Precisâo–SGS: investment, 201609 acquisition of 75% stake by SGS 2016-09-02
DiViNe project–Affilogic: vaccine purification technology, 201609 collab Affilogic is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–Aquaporin: vaccine purification technology, 201609 collab Aquaporin is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–EU (govt): grant, 201609c– Horizon 2020 grant 5y to advance vaccine purification led by iBET 2016-09-01
DiViNe project–GSK: vaccine purification technology, 201609 collab GSK Italy is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–iBET (PT): vaccine purification technology, 201609 collab GenIbet + iBET are partners in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–Merck (DE): vaccine purification technology, 201609– collab Merck is partner in Horizon 2020 project led by iBET 2016-09-01
Innovative Medicines Initiative–Lipotype: lipidomics, 201609– collab Lipotype is participant in RHAPSODY project on type 2 diabetes 2016-09-01
Phagenesis–Nestlé: investment, 201609– acquisition €na staged + milestone-based by Nestlé Health Science 2016-09-01
Rigontec–Germany (govt): business development, 201609– supply service support in US with German Accelerator Life Sciences programme 2016-09-01
Roche–Horizon Discovery: reference standards, 201609– collab developm + commercialisation of IHC Reference Standards with Ventana 2016-09-01
Zinsser Analytic–Kohlberg Kravis Roberts: investment, 201609 acquisition of ILS Gmbh + Zinsser Analytic GmbH from Mr+Ms Zinsser by Gardner Denver 2016-09-01
SPEware–Tecan: investment, 201608–201609 acquisition of SPEware for $50m in cash + $10m milestones 2016-08-31
Boehringer–Saniona: schizophrenia drugs, 201608– collab reserach €5m upfront + €85m milestones + royalties to identify compounds for schizophrenia 2016-08-29
Cyprotex–Danaher: mass spectrometer, 201608 supply two AB Sciex TripleTOF 6600 systems, one with Eksigent MicroLC + IonDrive + SWATH 2016-08-25
Cyprotex–Waters: mass spectrometer, 201608 supply existent of Xevo G2-XS QTof MS system used for mass metabolite identification studies 2016-08-25
Denali Therapeutics–F-Star: antibody technology, 201608– collab r+d bispecific antibodies for drug delivery across blood-brain barrier 2016-08-25
next pagenext page 1 2 3 ... 13 14 15 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top